Edition:
United States

EyeGate Pharmaceuticals Inc (EYEG.OQ)

EYEG.OQ on NASDAQ Stock Exchange Capital Market

1.24USD
3:59pm EST
Change (% chg)

$-0.03 (-2.36%)
Prev Close
$1.27
Open
$1.28
Day's High
$1.32
Day's Low
$1.18
Volume
114,344
Avg. Vol
28,881
52-wk High
$3.89
52-wk Low
$0.90

Chart for

About

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone... (more)

Overall

Beta: --
Market Cap(Mil.): $21.85
Shares Outstanding(Mil.): 17.20
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

BRIEF-EyeGate Achieves 75 Pct Enrollment In Pivotal Phase 3 Clinical Trial For Anterior Uveitis Triggering Milestone Payment

* EYEGATE ACHIEVES 75% ENROLLMENT IN PIVOTAL PHASE 3 CLINICAL TRIAL FOR ANTERIOR UVEITIS TRIGGERING MILESTONE PAYMENT

8:44am EST

BRIEF-Eyegate Pharmaceuticals posts Q3 ‍net loss $4.1 mln vs $3.4 mln a year ago

* Eyegate Pharmaceuticals reports third quarter 2017 financial results and provides business update

Nov 14 2017

BRIEF-EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery

* EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery

Nov 08 2017

BRIEF-Eyegate Pharmaceuticals Q2 revenue $148,000

* Eyegate Pharmaceuticals reports second quarter 2017 financial results and provides business update

Aug 07 2017

BRIEF-Eyegate Pharma enrolls first patient in phase 2b clinical study

* Eyegate Pharma enrolls first patient in phase 2b clinical study of EGP-437 for cataract surgery Source text for Eikon: Further company coverage:

Aug 01 2017

BRIEF-Armistice Capital LLC reports 9.9 percent passive stake in Eyegate Pharmaceuticals Inc

* Armistice Capital LLC reports 9.9 percent passive stake in Eyegate Pharmaceuticals Inc, as of June 9, 2017 Source text: (http://bit.ly/2sM4eCk) Further company coverage:

Jun 19 2017

Earnings vs. Estimates